Processes for preparing JAK inhibitors and related intermediate compounds

• US 8,993,582 B2
• Filed: 02/07/2013
• Issued: 03/31/2015
• Est. Priority Date: 01/15/2009
• Status: Active Grant

• Current Assignee: Incyte Holdings Corporation And Incyte Corporation
• Original Assignee: Incyte Corporation
• Inventors: Zhou, Jiacheng, Meloni, David, Liu, Pingli, Metcalf, Brian W., Yue, Tai-Yuen
• Primary Examiner(s): Murray, Jeffrey H
• Application Number:
  US13/761,830
• Publication Number:
  US 20130253193A1
• Time in Patent Office: 782 Days
• Field of Search: None
• US Class Current: 514/265.1
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07D 487/04 Ortho-condensed systems
• CPC Class Codes: C07F 5/025 Boronic and borinic acid compounds
• CPC Class Codes: C07F 7/083 Syntheses without formation of a Si-C bond
• CPC Class Codes: C07F 7/10 containing nitrogen having a Si-N linkage
• CPC Class Codes: C07F 7/1892 by reactions not provided for in C07F7/1876 - C07F7/1888
• CPC Class Codes: Y02P 20/55 Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Abstract

The present invention is related to processes for preparing chiral substituted pyrazolyl pyrrolo[2,3-d]pyrimidines of Formula III, and related synthetic intermediate compounds. The chiral substituted pyrazolyl pyrrolo[2,3-d]pyrimidines are useful as inhibitors of the Janus Kinase family of protein tyrosine kinases (JAKs) for treatment of inflammatory diseases, myeloproliferative disorders, and other diseases.

Claims

1. A process of preparing a composition comprising an enantiomeric excess of the (R)-enantiomer of a compound of Formula III′

;